Current clinical trials at Bay Area Hospital

S0337: A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer.  Further information available at http://clinicaltrials.gov/ct2/show/NCT00445601

 

CALGB40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery.  . The trial is studying several combinations of chemotherapy drugs given before surgery for patients with breast cancer. Further information available at http://clinicaltrials.gov/ct2/show/NCT00861705

 

CZOL446E2352: : Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer.  This trial is looking at the effectiveness of giving zoledronic acid (Zometa) every 4 weeks versus every 12 weeks over 1 year. This study is for women with breast cancer metastatic to the bone who have been on Zometa for 10 or more months. Further information available at http://clinicaltrials.gov/ct2/show/NCT00320710

 

S0221: A Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer. This trial is comparing 4 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage 1, 2, or 3 breast cancer. For more information please see http://clinicaltrials.gov/ct2/show/NCT00070564

 

S0500: Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy. This trial is studying treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy. Further information available at http://clinicaltrials.gov/ct2/show/NCT00382018

 

  

CALGB 30607: Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy. This trial is comparing how well sunitinib works when given as maintenance therapy compared to a placebo in patients with stage III or stage IV non-small cell lung cancer previously treated with combination chemotherapy. http://clinicaltrials.gov/ct2/show/NCT00693992

  

E1505: Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery. This trial is studying chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Further information available http://clinicaltrials.gov/ct2/show/NCT00324805

 

  

E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma. This clinical trial is studying ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III or stage IV melanoma that has been removed by surgery. Further information available http://clinicaltrials.gov/ct2/show/NCT01274338

 

  

S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid. TThis trial is gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid (Zometa) for bone metastases may help doctors learn more about the disease and provide the best follow-up care. Further information available http://clinicaltrials.gov/ct2/show/NCT00874211

 

 

E2905: Lenalidomide With or Without Epoetin Alfa in Treating Patients with Myelodysplastic Syndrome and Anemia. This trial is studying lenalidomide (Revlamid) to see how well it works with or without epoetin alfa (Procrit) in treating patients with myelodysplastic syndrome and anemia.

 

 

CALGB 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.  For further information see http://clinicaltrials.gov/ct2/show/NCT01238172

 

CALGB 90202: Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases. This trial is studying how well zoledronate acid (Zometa) works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases. For further information see http://clinicaltrials.gov/ct2/show/NCT00079001

 

CALGB 90203: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer. This trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer. Further information at http://clinicaltrials.gov/ct2/show/NCT00430183